Monoacylglycerol lipase inhibition-induced changes in plasma corticosterone levels, anxiety and locomotor activity in male CD1 mice

Hormones and Behavior

Volumn 63, Issue 5, 2013, Pages 752-758

  Aliczki, Mano ^a   Zelena, Dora ^a   Mikics, Eva ^a   Varga, Zoltan K ^a   Pinter, Otto ^a   Bakos, Nikoletta Venczkone ^a   Varga, Janos ^a   Haller, Jozsef ^a  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

Anxiety; CD1; Corticosterone; JZL184; Locomotion; Metyrapone; Monoacylglycerol lipase; Mouse; Stress

Indexed keywords

ACYLGLYCEROL LIPASE; CORTICOSTERONE; ENZYME INHIBITOR; JZL 184; METYRAPONE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; ENZYME INHIBITION; FORCED SWIMMING TEST; HORMONE SYNTHESIS; LOCOMOTION; MALE; MAZE TEST; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; TRANQUILIZING ACTIVITY;

ANIMALS; ANXIETY; BENZODIOXOLES; CORTICOSTERONE; ENZYME INHIBITORS; MALE; METYRAPONE; MICE; MONOACYLGLYCEROL LIPASES; MOTOR ACTIVITY; PIPERIDINES;

EID: 84878246519     PISSN: 0018506X     EISSN: 10956867     Source Type: Journal    
DOI: 10.1016/j.yhbeh.2013.03.017     Document Type: Article

References (45)

1. Aliczki M., Balogh Z., Tulogdi A., Haller J. The temporal dynamics of the effects of monoacylglycerol lipase blockade on locomotion, anxiety, and body temperature. Behav. Pharmacol. 2012, 23:348-357.
2. Arndt S.S., Laarakker M.C., van Lith H.A., van der Staay F.J., Gieling E., Salomons A.R., van't Klooster J., Ohl F. Individual housing of mice-impact on behaviour and stress responses. Physiol. Behav. 2009, 97:385-393.
3. Barna I., Csabai K., Makara G.B., Zelena D. Cannabinoid-mediated regulation of the hypothalamo-pituitary-adrenal axis in rats: age dependent role of vasopressin. Endocr. Regul. 2009, 43:13-21.
4. Benton D., Brain P.F. Behavioral and adrenocortical reactivity in female mice following individual or group housing. Dev. Psychobiol. 1981, 14:101-107.
5. Busquets-Garcia A., Puighermanal E., Pastor A., de la Torre R., Maldonado R., Ozaita A. Differential role of anandamide and 2-arachidonoylglycerol in memory and anxiety-like responses. Biol. Psychiatry 2011, 70:479-486.
6. Capanna E., Corti M., Mainardi D., Parmigiani S., Brain P.F. Karyotype and intermale aggression in wild house mice: ecology and speciation. Behav. Genet. 1984, 14:195-208.
7. Cole J.C., Rodgers R.J. An ethological analysis of the effects of chlordiazepoxide and bretazenil (Ro 16-6028) in the murine elevated plus-maze. Behav. Pharmacol. 1993, 4:573-580.
8. Cota D., Steiner M.A., Marsicano G., Cervino C., Herman J.P., Grubler Y., Stalla J., Pasquali R., Lutz B., Stalla G.K., Pagotto U. Requirement of cannabinoid receptor type 1 for the basal modulation of hypothalamic-pituitary-adrenal axis function. Endocrinology 2007, 148:1574-1581.
9. Cruz A.P., Frei F., Graeff F.G. Ethopharmacological analysis of rat behavior on the elevated plus-maze. Pharmacol. Biochem. Behav. 1994, 49:171-176.
10. Di S., Malcher-Lopes R., Halmos K.C., Tasker J.G. Nongenomic glucocorticoid inhibition via endocannabinoid release in the hypothalamus: a fast feedback mechanism. J. Neurosci. 2003, 23:4850-4857.
11. Di S., Malcher-Lopes R., Marcheselli V.L., Bazan N.G., Tasker J.G. Rapid glucocorticoid-mediated endocannabinoid release and opposing regulation of glutamate and gamma-aminobutyric acid inputs to hypothalamic magnocellular neurons. Endocrinology 2005, 146:4292-4301.
12. Fernandez Espejo E. Structure of the mouse behaviour on the elevated plus-maze test of anxiety. Behav. Brain Res. 1997, 86:105-112.
13. Ganon-Elazar E., Akirav I. Cannabinoid receptor activation in the basolateral amygdala blocks the effects of stress on the conditioning and extinction of inhibitory avoidance. J. Neurosci. 2009, 29:11078-11088.
14. Haller J., Halasz J., Makara G.B., Kruk M.R. Acute effects of glucocorticoids: behavioral and pharmacological perspectives. Neurosci. Biobehav. Rev. 1998, 23:337-344.
15. Hill M.N., McLaughlin R.J., Morrish A.C., Viau V., Floresco S.B., Hillard C.J., Gorzalka B.B. Suppression of amygdalar endocannabinoid signaling by stress contributes to activation of the hypothalamic-pituitary-adrenal axis. Neuropsychopharmacology 2009, 34:2733-2745.
16. Hill M.N., McLaughlin R.J., Bingham B., Shrestha L., Lee T.T., Gray J.M., Hillard C.J., Gorzalka B.B., Viau V. Endogenous cannabinoid signaling is essential for stress adaptation. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:9406-9411.
17. Johnson K.M., Dewey W.L., Ritter K.S., Beckner J.S. Cannabinoid effects on plasma corticosterone and uptake of 3H-corticosterone by mouse brain. Eur. J. Pharmacol. 1978, 47:303-310.
18. Kerr D.M., Burke N.N., Ford G.K., Connor T.J., Harhen B., Egan L.J., Finn D.P., Roche M. Pharmacological inhibition of endocannabinoid degradation modulates the expression of inflammatory mediators in the hypothalamus following an immunological stressor. Neuroscience 2012, 204:53-63.
19. Long J.Z., Li W., Booker L., Burston J.J., Kinsey S.G., Schlosburg J.E., Pavon F.J., Serrano A.M., Selley D.E., Parsons L.H., Lichtman A.H., Cravatt B.F. Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat. Chem. Biol. 2009, 5:37-44.
20. Long J.Z., Nomura D.K., Cravatt B.F. Characterization of monoacylglycerol lipase inhibition reveals differences in central and peripheral endocannabinoid metabolism. Chem. Biol. 2009, 16:744-753.
21. Long J.Z., Nomura D.K., Vann R.E., Walentiny D.M., Booker L., Jin X., Burston J.J., Sim-Selley L.J., Lichtman A.H., Wiley J.L., Cravatt B.F. Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:20270-20275.
22. Martin-Calderon J.L., Munoz R.M., Villanua M.A., del Arco I., Moreno J.L., de Fonseca F.R., Navarro M. Characterization of the acute endocrine actions of (?)-11-hydroxy-delta8-tetrahydrocannabinol-dimethylheptyl (HU-210), a potent synthetic cannabinoid in rats. Eur. J. Pharmacol. 1998, 344:77-86.
23. McLaughlin R.J., Hill M.N., Morrish A.C., Gorzalka B.B. Local enhancement of cannabinoid CB1 receptor signalling in the dorsal hippocampus elicits an antidepressant-like effect. Behav. Pharmacol. 2007, 18:431-438.
24. Mikics E., Kruk M.R., Haller J. Genomic and non-genomic effects of glucocorticoids on aggressive behavior in male rats. Psychoneuroendocrinology 2004, 29:618-635.
25. Mikics E., Barsy B., Barsvari B., Haller J. Behavioral specificity of non-genomic glucocorticoid effects in rats: effects on risk assessment in the elevated plus-maze and the open-field. Horm. Behav. 2005, 48:152-162.
26. Navarro J.F., Buron E., Martin-Lopez M. Anxiolytic-like activity of SB-205384 in the elevated plus-maze test in mice. Psicothema 2006, 18:100-104.
27. Pagotto U., Marsicano G., Fezza F., Theodoropoulou M., Grubler Y., Stalla J., Arzberger T., Milone A., Losa M., Di Marzo V., Lutz B., Stalla G.K. Normal human pituitary gland and pituitary adenomas express cannabinoid receptor type 1 and synthesize endogenous cannabinoids: first evidence for a direct role of cannabinoids on hormone modulation at the human pituitary level. J. Clin. Endocrinol. Metab. 2001, 86:2687-2696.
28. Patel S., Roelke C.T., Rademacher D.J., Cullinan W.E., Hillard C.J. Endocannabinoid signaling negatively modulates stress-induced activation of the hypothalamic-pituitary-adrenal axis. Endocrinology 2004, 145:5431-5438.
29. Pellow S., Chopin P., File S.E., Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Methods 1985, 14:149-167.
30. Porsolt R.D., Le Pichon M., Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977, 266:730-732.
31. Poshivalov V.P. The integrity of the social hierarchy in mice following administration of psychotropic drugs. Br. J. Pharmacol. 1980, 70:367-373.
32. Rodgers R.J., Cole J.C., Cobain M.R., Daly P., Doran P.J., Eells J.R., Wallis P. Anxiogenic-like effects of fluprazine and eltoprazine in the mouse elevated plus-maze: profile comparisons with 8-OH-DPAT, CGS 12066B, TFMPP and mCPP. Behav. Pharmacol. 1992, 3:621-634.
33. Romero E.M., Fernandez B., Sagredo O., Gomez N., Uriguen L., Guaza C., De Miguel R., Ramos J.A., Viveros M.P. Antinociceptive, behavioural and neuroendocrine effects of CP 55,940 in young rats. Brain Res. Dev. Brain Res. 2002, 136:85-92.
34. Rubino T., Guidali C., Vigano D., Realini N., Valenti M., Massi P., Parolaro D. CB1 receptor stimulation in specific brain areas differently modulate anxiety-related behaviour. Neuropharmacology 2008, 54:151-160.
35. Rubino T., Realini N., Castiglioni C., Guidali C., Vigano D., Marras E., Petrosino S., Perletti G., Maccarrone M., Di Marzo V., Parolaro D. Role in anxiety behavior of the endocannabinoid system in the prefrontal cortex. Cereb. Cortex 2008, 18:1292-1301.
36. Saber-Tehrani A., Naderi N., Hosseini Najarkolaei A., Haghparast A., Motamedi F. Cannabinoids and their interactions with diazepam on modulation of serum corticosterone concentration in male mice. Neurochem. Res. 2010, 35:60-66.
37. Sano K., Koushi E., Irie K., Higuchi S., Tsuchihashi R., Kinjo J., Egashira N., Oishi R., Uchida N., Nagai H., Nishimura R., Tanaka H., Morimoto S., Mishima K., Iwasaki K., Fujiwara M. Delta(9)-tetrahydrocannabinol enhances an increase of plasma corticosterone levels induced by forced swim-stress. Biol. Pharm. Bull. 2009, 32:2065-2067.
38. Sciolino N.R., Zhou W., Hohmann A.G. Enhancement of endocannabinoid signaling with JZL184, an inhibitor of the 2-arachidonoylglycerol hydrolyzing enzyme monoacylglycerol lipase, produces anxiolytic effects under conditions of high environmental aversiveness in rats. Pharmacol. Res. 2011, 64:226-234.
39. Toth M., Mikics E., Tulogdi A., Aliczki M., Haller J. Post-weaning social isolation induces abnormal forms of aggression in conjunction with increased glucocorticoid and autonomic stress responses. Horm. Behav. 2011, 60:28-36.
40. Wall P.M., Blanchard R.J., Yang M., Blanchard D.C. Infralimbic D2 receptor influences on anxiety-like behavior and active memory/attention in CD-1 mice. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003, 27:395-410.
41. Weidenfeld J., Feldman S., Mechoulam R. Effect of the brain constituent anandamide, a cannabinoid receptor agonist, on the hypothalamo-pituitary-adrenal axis in the rat. Neuroendocrinology 1994, 59:110-112.
42. Wenger T., Jamali K.A., Juaneda C., Leonardelli J., Tramu G. Arachidonyl ethanolamide (anandamide) activates the parvocellular part of hypothalamic paraventricular nucleus. Biochem. Biophys. Res. Commun. 1997, 237:724-728.
43. Wenger T., Ledent C., Tramu G. The endogenous cannabinoid, anandamide, activates the hypothalamo-pituitary-adrenal axis in CB1 cannabinoid receptor knockout mice. Neuroendocrinology 2003, 78:294-300.
44. Zarrindast M.R., Sarahroodi S., Arzi A., Khodayar M.J., Taheri-Shalmani S., Rezayof A. Cannabinoid CB1 receptors of the rat central amygdala mediate anxiety-like behavior: interaction with the opioid system. Behav. Pharmacol. 2008, 19:716-723.
45. Zuardi A.W., Teixeira N.A., Karniol I.C. Pharmacological interaction of the effects of delta 9-trans-tetrahydrocannabinol and cannabidiol on serum corticosterone levels in rats. Arch. Int. Pharmacodyn. Ther. 1984, 269:12-19.